Testing two first-treatment options for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have confirmed advanced epithelial ovarian cancer (or primary peritoneal or fallopian-tube cancer), stage III or IV
- Have had surgery within the last 3 weeks (either debulking or diagnostic surgery)
- Be 18 to under 75 years old
- Be able to do normal daily activities with limited impairment (overall health score not too low)
- Blood tests and kidney function must be adequate (white blood cells, platelets, and creatinine clearance)
- Not have had prior chemotherapy for ovarian cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways of treating advanced ovarian cancer: having surgery first, or having chemotherapy first followed by surgery. The goal is to see which approach improves outcomes for patients.
This Phase 3 trial compares two chemotherapy drug approaches (nab-paclitaxel vs another taxane drug) as the first treatment for advanced ovarian, fallopian tube, or peritoneal cancer. It aims to find which option works better and is tolerated better in people with stage III–IV disease.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This study tests a personalized cancer therapy designed just for you and your tumor. It is for people with newly diagnosed advanced ovarian cancer who can wait a short time before starting treatment and plan to have surgery after 2 cycles of chemotherapy.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
Hear when a new Ovarian Cancer, Epithelial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.